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Alzheimer’s risk variants in the clusterin gene are
associated with alternative splicing
M Szymanski
1, R Wang
2, SS Bassett
2 and D Avramopoulos
1,2
Genetic variation in CLU encoding clusterin has been associated with Alzheimer’s disease (AD) through replicated genome-
wide studies, but the underlying mechanisms remain unknown. Following earlier reports that tightly regulated CLU alternative
transcripts have different functions, we tested CLU single-nucleotide polymorphisms (SNPs), including those associated with
AD for quantitative effects on individual alternative transcripts. In 190 temporal lobe samples without pathology, we found that
the risk allele of the AD-associated SNP rs9331888 increases the relative abundance of transcript NM_203339 (P¼4.3 10
 12).
Usinganindependentsetof115ADandcontrolsamples,wereplicatedthisresult(P¼0.0014)andfurtherobservedthatmultiple
CLU transcripts are at higher levels in AD compared with controls. The AD SNP rs9331888 is located in the ﬁrst exon of
NM_203339 and therefore, it is a functional candidate for the observed effects. We tested this hypothesis by in vitro dual
luciferase assays using SK-N-SH cells and mouse primary cortical neurons and found allelic effects on enhancer function,
consistent with our results on post-mortem human brain. These results suggest a biological mechanism for the genetic
association of CLU with AD risk and indicate that rs9331888 is one of the functional DNA variants underlying this association.
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Introduction
Two recent genome-wide association studies independently
identiﬁed CLU as a risk gene for Alzheimer’s disease (AD).
1,2
Follow-up studies and meta analyses have replicated these
results, although the strongest associated variant sometimes
differed.
3–7 Efforts to identify functional variations through
exon sequencing and examining effects of single-nucleotide
polymorphisms (SNPs) on CLU expression have not yet
provided a functional link between the associated polymor-
phisms and AD, but they have excluded the involvement of
common coding variation.
8 The same study examined the
effect of SNPs on the gene’s expression with negative results;
however, the microarray platform used did not examine
individual splice variants.
Clusterin, also known as apolipoprotein J, is a glycoprotein
ﬁrst identiﬁed in 1988
9 and discussed as a candidate gene for
AD for more than 15 years.
10,11 Its multiple functions include
roles in apoptosis, complement regulation, lipid transport,
sperm maturation, endocrine secretion, membrane protec-
tion, promotion of cell interactions and as a chaperone.
12–16
Secreted soluble and nuclear forms of clusterin have been
described and their production is likely regulated by use of
alternative transcription start sites
17 or alternative splicing.
13
This is achieved through use of discrete translation initiation
sites, alternatively introducing an endoplasmic reticulum-
targeting signal upstream of a nuclear localization signal.
The nuclear form of clusterin is speciﬁcally induced in
epithelialcellsbytumorgrowthfactor-b,
17whereasinprostate
cells, different CLU isoforms have been shown to have
different responses to androgens and opposing functions with
regard to apoptosis.
18,19
The importance of CLU alternative splicing on its function
led us to the hypothesis that the reported association with AD,
although it is shown not to have a signiﬁcant impact on the
overall transcript levels as measured by microarrays,
8 might
reﬂect a disruption of the balance between transcripts.
We tested our hypothesis on a set of 190 temporal lobe
samples without brain pathology (controls) and followed up in
another set of 115 temporal lobe samples from AD cases and
controls.
Materials and methods
Samples. Tissue samples were acquired from the Harvard
Brain Tissue Resource Center (HBTRC) and the Johns
Hopkins Brain Resource Center, dissected from the superior
temporal lobe (Brodmann area 22) of ﬂash-frozen brain
slices from donors, without macroscopically visible brain
pathology or with deﬁnite AD (replication set), and stored
at  801C. Detailed information on all individual samples
including age at death, sex and post-mortem tissue collection
interval (PMI) are provided in Supplementary Table 1.
Genomic DNA was extracted from 10mg of tissue using
the Gentra Puregene Tissue Kit (Qiagen, Valencia, CA, USA)
following manufacturer’s protocol. RNA was extracted from
30mg of tissue using the RNeasy Lipid Tissue Mini Kit
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www.nature.com/tp(Qiagen). Reverse transcription reactions on total RNA
were performed using GeneAmp RNA PCR Kit (Applied
Biosystems, Carlsbad, CA, USA) and random hexamer
primers following standard protocols. All real-time PCR experi-
ments on each set of samples (discovery or replication) were
done on the same set of reverse-transcribed RNAs to assure
template consistency across transcripts minimizing experi-
mental noise.
Genotyping. Genotyping was performed at the Johns
Hopkins SNP center on a custom SNP panel, using the
Illumina GoldenGate platform (Illumina Inc., San Diego, CA,
USA). We attempted 76 SNPs, and the SNP center released
70 SNPs after considering adequate clustering deﬁnitions,
SNP call rate and intensity. Two released SNPs were ﬂagged
for atypical clustering and we removed them from analysis.
Among the SNPs not released was rs11136000, which
we wanted to analyze, as it is the most consistently
associated SNP with AD. We used the Beadstudio
software (lllumina Inc.) and found that the separation of
alleles was clear (Supplementary Figure 1). Nevertheless,
we re-genotyped this SNP using an ApoI restriction enzyme
digestion assay and after conﬁrming the genotypes, we
included them in our analysis (see primers in Supplementary
Table 2). Despite good quality data, we also decided to
re-genotype and conﬁrm rs9331888 by nucleotide sequen-
cing, as it is important to our conclusions. In the replication
sample, rs9331888 was genotyped by BslI restriction
digestion, using the primers shown in Supplementary Table
2. All restriction enzyme digestion assays included control
restriction sites that conﬁrmed complete digestion. All SNPs
are shown in Supplementary Table 3 with their location,
genotype frequencies, Hardy–Weinberg equilibrium and
allele identities.
Real-time PCR. Real-time PCR reactions were performed in
triplicate using the SYBR Green qPCR Detection System
(Invitrogen, Carlsbad, CA, USA). SYBR Green was preferred
to the TaqMan chemistry (Applied Biosystems, Carlsbad,
CA, USA), because it provides more ﬂexibility in primer
design, which was necessary for splice variant-speciﬁc
assays. All PCR products were designed with one primer’s
30 end, overlapping by a few nucleotides the isoform-speciﬁc
splice junction. All primer sequences are reported in
Supplementary Table 2. Amplicon sequences were veriﬁed
by Sanger sequencing. Gel electrophoresis and melting
curves further conﬁrmed that a single product was ampliﬁed
and measured by the assays. Samples in triplicate in the
discovery set were run on two separate 384-well plates,
where they were randomly distributed (as shown in
Supplementary Table 1). Plate identity was accounted for
in the analyses as described below. Real-time measure-
ments were made on an Applied Biosystems 7900HT
sequence detection system and measurements were
converted to relative quantities using six serial twofold
dilutions in triplicate. Triplicates for all samples and
standards were examined for outlier measurements that
were removed if present. On the basis of the literature
on optimal normalization controls, we chose three genes,
ACTB, POLR2F and MRIP, to control for variations in RNA
input and reverse transcription efﬁciency.
20,21 We performed
real-time experiments for all three, compared their inter-
sample variability and their pair-wise correlations, and used
for normalization the mean of the least variable and most
correlated pair, ACTB and MRIP. The normalized values
were log transformed (base 2) to achieve a normal
distribution before proceeding to statistical analysis.
Statistical analyses. SNP genotypes were coded in a
quantitative manner (0, 1 or 2 alleles B—see Supple-
mentary Table 3 for allele identities). Principal component
(PC) analyses of the ancestry informative SNP marker SNPs
were performed in R, using the ‘principal()’ function in
the ‘psych’ package (Revelle, W. 2011, Northwestern
University (Chicago, IL, USA), R package version 1.0–95),
replacing missing genotypes with the population’s mean for
the corresponding SNP. Statistical analyses of normalized
log-transformed expression data were also performed in R,
using the ‘glm’ function for ﬁtting generalized linear models
with formulas as described in the text, an identity link func-
tion and a Gaussian distribution. Log-transformed trans-
cript measurements were tested for normality of the
distributions, using the Kolmogorov–Smirnov test. All were
normally distributed (P40.1) in the discovery data set. In the
replication set, small deviations from normality were seen for
transcripts NM_001171138 and CR617497 (P¼0.03 and
P¼0.01, respectively), not signiﬁcant after correcting for six
tests. Statistical comparisons of intensities between
constructs in the dual luciferase reporter assays were
performed by Student’s t-test, comparing the two alleles
of each construct across the four observations from
quadruplicate experiments. All results are reported without
corrections for multiple comparisons, deemed unnecessary,
given the robustness of all P-values for the reported main
effects and the consistency of results, both in the original
analyses and in replications.
Luciferase reporter assays. Constructs: The upstream (U),
short (S) and downstream (D) inserts (shown in Figure 1c
were PCR ampliﬁed from genomic DNA from individuals
homozygous for the reference or risk alleles for rs9331888
(primers in Supplementary Table 2). Sequencing revealed no
other variation in the ampliﬁed sequence. Fragments were
ampliﬁed using PfuTurbo Polymerase (Stratagene, Santa
Clara, CA, USA) high-ﬁdelity taq, and A’ overhangs were
added by incubating the products for 5min with Taq
DNA polymerase (Invitrogen) and excess deoxyadenosine
triphosphate. The amplicons were TA cloned into pCR 8/GW/
TOPO (lnvitrogen) entry vector containing attL1 and attL2
recombination sites. Inserts were subcloned via recom-
bination, using the Gateway LR Clonase Enzyme Mix
(Invitrogen) to a pDSma_promoter vector.
22 This plasmid
is a pGL3 ﬁreﬂy luciferase reporter vector containing
an SV40 promoter (Promega, Madison, WI, USA), modi-
ﬁed to contain the Gateway cassette containing the attA
and attB recombination sites as described in Grice et al.
22
Inserts were veriﬁed by Sanger sequencing using the
commercial primer RVprimer3 (Promega) and pGLR 50
(Supplementary Table 2). Neuroblastoma (SK-N-SH, ATCC
no. HTB-11) cells were grown in an ATCC-suggested
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Translational Psychiatrymedium (http://www.atcc.org), without antibiotics. Approxi-
mately 0.8 10
5 cells were plated 24h before transfection
for cells to reach 90–95% conﬂuency. Primary cortical
neuron cultures were prepared from day 16–18 embryonic
C57BL/6 mice, following established protocols.
23 Animal
protocols were approved by Johns Hopkins University
Animal Care and Use Committee. Primary cortical neurons
were plated in 24-well plates at a density of 2 10
5 in 1ml of
growth medium per well. The neurons were switched to
500ml antibiotic-free medium on the third day in vitro and
transfected on day 4. SK-N-SH and primary cortical neurons
were co-transfected (Lipofectamine 2000, Invitrogen) using
0.8mg of plasmid DNA and 0.08mg phRL-SV40 control renilla
plasmid, using standard 24-well protocol. Medium was
replaced 5h post transfection. Dual luciferase assays
(Promega) were performed in quadruplicate 24h post
transfection, following the manufacturers standard protocol
(Tecan Genios Microplate Reader, Ma ¨nnedorf, Switzerland).
Relative luciferase units were calculated by dividing the ﬁreﬂy
luciferase values by the renilla control values for each
transfection reaction.
Results
Three different CLU splice forms with different transcription
start sites (Figure 1a) are reported in RefSeq
24 (NM_001831,
NM_203339 and NM_001171138) and can be differentiated
using sequence-speciﬁc primers for quantitative real-time
Figure 1 (a)CLUalternativetranscriptsfromreferencesequence(RefSeq)andUCSCexaminedinthisstudy.Single-nucleotidepolymorphisms(SNPs)genotypedwithin
the gene are shown and SNPs reported in recent genome-wide association studies (GWAS) are marked with an asterisk. (b) Enlargement of the region around rs9331888.
The SNP location is marked by a vertical red line. Selected tracks from the UCSC genome browser ENCODE data, as well as phylogenetic conservation data are shown. For
clariﬁcations, see the UCSC genome database website. (c) The sequences inserted into reporter constructs are shown named U (upstream) S (short) and D (downstream).
Each sequence was made to carry either a reference or a risk allele at rs9331888, shown here by a white asterisk and found to inﬂuence Alzheimer’s disease (AD) risk in the
Lambert et al.
2 GWAS.
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Translational PsychiatryPCR. All RefSeq transcripts include coding sequence for
both the endoplasmic reticulum-targeting signal and the
nuclear localization signal, but whether they all use the
upstream translation start site and include both signals in
the protein is unknown. In our experiments using brain
RNA, we did not observe the transcript lacking exon 2
described in a breast cancer cell line,
13 but we found a
transcript reported in the UCSC genome browser (GenBank
acc# CR617497) lacking exons 1, 3 and 4, thus missing
both the endoplasmic reticulum-targeting signal and nuclear
localization signal. We designed speciﬁc primers (Supple-
mentary Table 2) and successfully ampliﬁed NM_203339,
NM_001171138 and CR617497. We conﬁrmed that single
and speciﬁc amplicons were ampliﬁed from each transcript
by Sanger sequencing, agarose gel electrophoresis and
DNA melting curves. Using real-time PCR, we quantiﬁed
the transcripts in tissue from the superior temporal lobe of
190 individuals without gross brain pathogy (‘controls’)
obtained from the HBTRC (see Supplementary Table 2 for
sample details). We extracted brain DNA from the same
individuals and successfully genotyped 42 HapMap SNPs
in and around CLU, chosen to be inter-correlated at r
2p0.8
and including the associated SNPs reported in the two ﬁrst
genome-wide association studies reporting CLU.
1,2 Further,
we genotyped 27 ancestry informative SNP markers,
25 as the
HBTRC did not retain ancestry information (Supplementary
Table 3 describes all study SNPs).
We ﬁrst examined the ancestry informative SNP markers
in a PC analysis and identiﬁed two outlier individuals for
PC-1, likely of African ancestry, who were removed from
further analysis. No additional PCs showed outliers. Using
log-transformed transcript quantity as an outcome, we
applied a generalized linear model including age, sex, PMI,
PCR plate ID (identity) (to account for plate effects as we
used two 384-well real-time plates) and the ﬁrst PC of the
ancestry informative SNP markers to account for possible
residual admixture. We found a highly signiﬁcant increase
for all transcripts with increasing age (about 1% increase
per year, all P-values o0.0002, see Table 1), consistent with
our recent report of signiﬁcant overlap between genes
changing expression in AD and with normal aging.
26
Transcript CR617497 was signiﬁcantly lower in males
(B17%,P¼0.001)andNM_203339approachedsigniﬁcance
for an approximate 13% decrease in males (P¼0.058). A
signiﬁcant plate effect was identiﬁed only for transcript
NM_001171138 and no effects of PMI were identiﬁed. Plate
ID and PMI were both included in all analyses to account for
possible small effects, regardless of signiﬁcance. Trans-
cript expression levels showed strong positive inter-correla-
tions persisting after correcting for all the effects in our
model, possibly suggesting signiﬁcant common regulation
(all Po10
 4). We then included each SNP genotype
sequentially as a predictor in the model. The results for the
three transcripts for SNPs showing at least nominally
signiﬁcant effects on transcription are shown on the left side
of Table 2. The SNP variants had little or no effect on
NM_001171138 and CR617497. In contrast, NM_203339
showed multiple, nominally signiﬁcant correlations with
genotypes, the strongest with rs9331888. This SNP, located
in exon 1 of NM_203339 (Figure 1b) ranked third in the
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Translational Psychiatryrecent genome-wide association studies on Caucasians by
Lambert et al.
2 and was the only one of the three SNPs
that replicated in an independent study of a Chinese
population,
6 although contradicting results have been
reported,
27 providing strongest support for a different SNP,
rs11136000. The risk alleles of rs11136000 and rs9331888
are in strong linkage disequilibrium (D’¼0.96, r
2¼0.224
based on our data). We then examined the effect of
SNP genotypes on each transcript, adjusting for the amount
of the other two transcripts, which were added as predictors
in the model. This analysis reﬂects regulation of alterna-
tive splicing by removing variability common to all trans-
cripts and highlighting their differences. The results of this
analysis (Table 2, right side) showed a highly signiﬁcant
effect of rs9331888 on the relative levels of NM_203339
(P¼4.3 10
 12). To test whether other less signiﬁcant
effects on NM_203339 observed for SNPs rs11136000,
rs9331908, rs9331931, rs3087554 and rs17466684 were
due to linkage disequilibrium, we analyzed each in a model
that also included rs9331888. In all cases, only rs9331888
remained signiﬁcant, suggesting that other SNP effects
on splicing likely reﬂect their linkage disequilibrium with
rs9331888.
To exclude artifacts, we performed multiple quality-control
steps. We excluded nucleotide variation under a PCR primer
by sequencing the regions under the NM_203339-speciﬁc
primers in all individuals. Additionally, we designed a new set
of transcript-speciﬁc primers for NM_203339 and CR617497,
and performed new quantitative PCR experiments starting
from RNA, obtaining similar highly signiﬁcant results. We only
used CR617497 in this experiment, because the original data
showed that correcting NM_203339 for just one other
transcript revealed the effect almost equally well as correcting
forboth.Wefurthertestedforgenotypingerrorsandconﬁrmed
by nucleotide sequencing all rs9331888 genotypes.
We proceeded to replicate our result in an independent
set of samples, which included AD cases allowing us to test
for possible disease-related transcript variation. This replica-
tion set included 24 controls from the HBTRC and 29 controls
from the Johns Hopkins Brain Resource Center, as well as
22and40ADcases,respectively.WequantiﬁedNM_203339,
NM_001171138 and CR617497 as above, genotyped
rs9331888 by sequencing and by BslI restriction enzyme
digestion and applied a similar generalized linear model, with
NM_203339 as a dependent variable, age, sex, PMI, sample
source, diagnosis and rs9331888 genotype as predictors.
The quantitative PCR plate variable no longer applied, as a
single plate was used in this experiment. We used existing
ancestry information on the Johns Hopkins Brain Resource
Center samples and included only Caucasian individuals.
Ancestry information was not available for HBTRC samples,
but as we identiﬁed only two genetic outliers in the previous
larger HBTRC sample and observed no signiﬁcant effects of
ethnicity, we included all HBTRC samples. The effect of
rs9331888 on relative NM_203339 levels was strongly
replicated (P¼0.0014, Table 2). As with the initial sample,
the signiﬁcance of the effect on total mRNA levels was
more modest, this time only suggestive (P¼0.076). Cases
had higher levels of all transcripts (Table 1) and suggestively
higher levels of relative levels of NM_203339. After correcting
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Translational Psychiatryfor the effect of rs9331888, the difference in relative levels
of NM_203339 between AD cases and controls was dimin-
ished. Many of the previously observed effects of age and sex
on the various transcripts were replicated in this sample as
shown in Table 1.
The location of rs9331888 in exon 1 of NM_203339,
together with ChIP-seq and DNase hypersensitivity
data from ENCODE (encyclopedia of DNA elements; see
Figure 1b), suggest that this variant might be directly
responsible for regulation of this alternative transcription
start. We used the Promega Dual-Luciferase Reporter Assay
System to test the six expression constructs shown in
Figure 1c (S-ref, S-risk, U-ref, U-risk, D-ref and D-risk; ref
and risk indicate the rs9331888 alleles) for enhancer activity
in SK-N-SH cells and primary mouse cortical neurons. We
observed signiﬁcantly higher activity of the risk allele for all
constructs in primary neurons and the S- and U- constructs in
SK-N-SH cells (Figure 2), consistent with our post-mortem
brain expression results.
As shown in Figure 1, rs9331888 lies in a region with
signiﬁcant evidence of regulatory potential. We used the
bioinformatics program rVista 2.0 (http://rvista.dcode.org/)
28
and found that the risk variant of rs9331888 eliminates bind-
ing sites for nuclear factor kappa B and early B-cell factor,
whereas it generates a new binding site for heat shock factor
protein-1. Pending experimental veriﬁcations, this interesting
result could provide a guide for further dissection of the
relationship between this SNP, this transcript and AD.
Discussion
We have shown that the minor allele of rs9331888, previously
associated with increased risk of AD, is associated with
increased-relative levels of NM_203339 and is likely the
functional variant responsible for this effect. Given the prior
genetic association results for this SNP and the distinct roles
of CLU transcripts,
18 we hypothesize that alternative splicing
is the etiological link between rs9331888 and AD. However,
the functional properties of the protein products and whether
or how their production varies across the three transcripts
are unclear. At least two transcripts, NM_001171138 and
NM_203339, potentially contain both the endoplasmic reticu-
lum-targeting signal and nuclear localization signal, but it is
unknown whether there is preferential utilization of a speciﬁc
translation start site, which could dramatically change the
functional outcome.
18,19 Finally, the function of CR617497
which we were able to reliably detect in the temporal lobe
transcriptome is unknown. An alternative hypothesis is that
the increased risk is not the result of the different transcript
functions, but rather of their speciﬁc responses to different
signals, responses that might be aberrantly lost or gained for
carriers of the rs9331888 risk allele, which abolishes two
and introduces one new transcription factor binding site.
Regardless of what the true underlying biology will turn out
to be, in view of our results and the reported genome-wide
association studies, clarifying the properties of these trans-
cripts, the corresponding proteins and their regulation is of
great importance for AD research.
As we mentioned in the introduction, although rs9331888
has been independently reported in two populations, it is
another CLU SNP, rs11136000 that has shown overall the
most consistent associations. As the two risk alleles are in
near complete linkage disequilibrium with each other
(D’¼0.96), it is likely that the functional effect of rs9331888
is responsible for only part of the observed association of the
genewithAD.Otherrareorcommonregulatoryvariantsmight
underlie the remaining risk attributed to CLU and the
inconsistencies in association patterns described in the
literature. Further clariﬁcation of these effects remains a
signiﬁcant task, which will be facilitated by this and future
work, testing the new hypotheses and moving translational
research forward. Together with the recent many advances in
AD through new gene discovery, our understanding of the
disease biology will quickly improve, hopefully leading to
signiﬁcant beneﬁts for the patients and those at risk.
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Figure 2 Dual luciferase reporter assays comparing constructs carrying
reference (ref) or risk alleles in the three different constructs shown in Figure 1c in
front of an SV40 promoter. Fireﬂy, relative to renilla luciferase levels, is shown with
s.e. bars based on four replicates. All constructs show signiﬁcant differences
between the two rs9331888 alleles in primary neuron culture and two of three also
show differences in SK-N-SH cells. As expected, the risk allele shows higher
activity. RLU, relative luciferase units.
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